The U.S. Food and Drug Administration (FDA) has accepted for filing PTC Therapeutics’ New Drug Application (NDA) for ...

Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...

Holdings announced its plans to advance the development of its proprietary Antibody Drug Conjugate (ADC) platform ...

PTC Therapeutics (PTCT) announced that the U.S. Food and Drug Administration, FDA, has accepted for filing the New Drug Application, NDA, for ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

A lawsuit filed in the Singapore International Commercial Court is seeking $830 million in damages from KBP, with Novo ...

Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing ...

A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...

Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...